Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 5858315, 13 pages
https://doi.org/10.1155/2017/5858315
Research Article

A Novel Role for Brain Natriuretic Peptide: Inhibition of IL-1 Secretion via Downregulation of NF-kB/Erk 1/2 and NALP3/ASC/Caspase-1 Activation in Human THP-1 Monocyte

Department of Experimental Medicine, University of Perugia, Piazzale L. Severi 1, 06129 Perugia, Italy

Correspondence should be addressed to Letizia Mezzasoma; ti.gpinu@amosazzem.aizitel

Received 8 September 2016; Revised 15 December 2016; Accepted 18 January 2017; Published 26 February 2017

Academic Editor: Hermann Gram

Copyright © 2017 Letizia Mezzasoma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. A. Dinarello, “Immunological and inflammatory functions of the interleukin-1 family,” Annual Review of Immunology, vol. 27, pp. 519–550, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. B. R. Barker, D. J. Taxman, and J. P.-Y. Ting, “Cross-regulation between the IL-1β/IL-18 processing inflammasome and other inflammatory cytokines,” Current Opinion in Immunology, vol. 23, no. 5, pp. 591–597, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Martinon, A. Mayor, and J. Tschopp, “The inflammasomes: guardians of the body,” Annual Review of Immunology, vol. 27, pp. 229–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Menu and J. E. Vince, “The NLRP3 inflammasome in health and disease: the good, the bad and the ugly,” Clinical and Experimental Immunology, vol. 166, no. 1, pp. 1–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. B. K. Davis, H. Wen, and J. P.-Y. Ting, “The inflammasome NLRs in immunity, inflammation, and associated diseases,” Annual Review of Immunology, vol. 29, pp. 707–735, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Bryant and K. A. Fitzgerald, “Molecular mechanisms involved in inflammasome activation,” Trends in Cell Biology, vol. 19, no. 9, pp. 455–464, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. I. C. Allen, M. A. Scull, C. B. Moore et al., “The NLRP3 inflammasome mediates in vivo innate immunity to influenza a virus through recognition of viral RNA,” Immunity, vol. 30, no. 4, pp. 556–565, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Chakraborty, D. K. Kaushik, M. Gupta, and A. Basu, “Inflammasome signaling at the heart of central nervous system pathology,” Journal of Neuroscience Research, vol. 88, no. 8, pp. 1615–1631, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Daheshia and J. Q. Yao, “The interleukin 1β pathway in the pathogenesis of osteoarthritis,” Journal of Rheumatology, vol. 35, no. 12, pp. 2306–2312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Dombrowski, M. Peric, S. Koglin et al., “Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions,” Science Translational Medicine, vol. 3, no. 82, Article ID 82ra38, 2011. View at Publisher · View at Google Scholar
  11. C. M. Artlett, “Inflammasomes in wound healing and fibrosis,” Journal of Pathology, vol. 229, no. 2, pp. 157–167, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. N. A. Thornberry, H. G. Bull, J. R. Calaycay et al., “A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes,” Nature, vol. 356, no. 6372, pp. 768–774, 1992. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Papoutsopoulou, A. Symons, T. Tharmalingham et al., “ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses,” Nature Immunology, vol. 7, no. 6, pp. 606–615, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Jo, J. K. Kim, D. Shin, and C. Sasakawa, “Molecular mechanisms regulating NLRP3 inflammasome activation,” Cellular and Molecular Immunology, vol. 13, no. 2, pp. 148–159, 2015. View at Publisher · View at Google Scholar
  15. B. Hoesel and J. A. Schmid, “The complexity of NF-κB signaling in inflammation and cancer,” Molecular Cancer, vol. 12, article 86, 2013. View at Publisher · View at Google Scholar
  16. P. P. Roux and J. Blenis, “ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions,” Microbiology and Molecular Biology Reviews, vol. 68, no. 2, pp. 320–344, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Gantke, S. Sriskantharajah, M. Sadowski, and S. C. Ley, “IκB kinase regulation of the TPL-2/ERK MAPK pathway,” Immunological Reviews, vol. 246, no. 1, pp. 168–182, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. McCubrey, L. S. Steelman, W. H. Chappell et al., “Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1773, no. 8, pp. 1263–1284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, “Gout-associated uric acid crystals activate the NALP3 inflammasome,” Nature, vol. 440, no. 7081, pp. 237–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. R. W. Grant and V. D. Dixit, “Mechanisms of disease: inflammasome activation and the development of type 2 diabetes,” Frontiers in Immunology, vol. 4, article 50, 2013. View at Publisher · View at Google Scholar
  21. R. Stienstra, J. A. Van Diepen, C. J. Tack et al., “Inflammasome is a central player in the induction of obesity and insulin resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 37, pp. 15324–15329, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. A.-C. Villani, M. Lemire, G. Fortin et al., “Common variants in the NLRP3 region contribute to Crohn's disease susceptibility,” Nature Genetics, vol. 41, pp. 71–76, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Hornung, F. Bauernfeind, A. Halle et al., “Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization,” Nature Immunology, vol. 9, no. 8, pp. 847–856, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Okamoto, W. Liu, Y. Luo et al., “Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1β,” Journal of Biological Chemistry, vol. 285, no. 9, pp. 6477–6488, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Halle, V. Hornung, G. C. Petzold et al., “The NALP3 inflammasome is involved in the innate immune response to amyloid-β,” Nature Immunology, vol. 9, no. 8, pp. 857–865, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. M. T.-H. Huang, D. J. Taxman, E. A. Holley-Guthrie et al., “Critical role of apoptotic speck protein containing a caspase recruitment domain (ASC) and NLRP3 in causing necrosis and asc speck formation induced by Porphyromonas gingivalis in human cells,” The Journal of Immunology, vol. 182, no. 4, pp. 2395–2404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. S. K. Ippagunta, D. D. Brand, J. Luo et al., “Inflammasome-independent role of apoptosis-associated speck-like protein containing a CARD (ASC) in T cell priming is critical for collagen-induced arthritis,” Journal of Biological Chemistry, vol. 285, no. 16, pp. 12454–12462, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. D. J. Taxman, E. A. Holley-Guthrie, M. Tze-Han Huang et al., “The NLR adaptor ASC/PYCARD regulates DUSP10, mitogen-activated protein kinase (MAPK), and chemokine induction independent of the inflammasome,” Journal of Biological Chemistry, vol. 286, no. 22, pp. 19605–19616, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. Q. He and M. C. LaPointe, “Interleukin-1β regulates the human brain natriuretic peptide promoter via Ca2+-dependent protein kinase pathways,” Hypertension, vol. 35, no. 1, pp. 292–296, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. L. R. Potter, A. R. Yoder, D. R. Flora, L. K. Antos, and D. M. Dickey, “Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications,” in cGMP: Generators, Effectors and Therapeutic Implications, vol. 191 of Handbook of Experimental Pharmacology, pp. 341–366, Springer, 2009. View at Publisher · View at Google Scholar
  31. S. P. D'Souza, M. Davis, and G. F. Baxter, “Autocrine and paracrine actions of natriuretic peptides in the heart,” Pharmacology and Therapeutics, vol. 101, no. 2, pp. 113–129, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Hama, H. Itoh, G. Shirakami et al., “Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction,” Circulation, vol. 92, no. 6, pp. 1558–1564, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. O. Nakagawa, Y. Ogawa, H. Itoh et al., “Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. evidence for brain natriuretic peptide as an ‘emergency’ cardiac hormone against ventricular overload,” Journal of Clinical Investigation, vol. 96, no. 3, pp. 1280–1287, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. K. N. Pandey, “Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes phosphoinositide hydrolysis, Ca2+ release, and activation of protein kinase C,” Frontiers in Molecular Neuroscience, vol. 7, article 75, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Glezeva, P. Collier, V. Voon et al., “Attenuation of monocyte chemotaxis-a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide,” Journal of Cardiovascular Translational Research, vol. 6, no. 4, pp. 545–557, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. V. Chiurchiù, V. Izzi, F. D'Aquilio, F. Carotenuto, P. Di Nardo, and P. M. Baldini, “Brain natriuretic peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages,” Regulatory Peptides, vol. 148, no. 1-3, pp. 26–32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Ogawa and A. J. de Bold, “Brain natriuretic peptide production and secretion in inflammation,” Journal of Transplantation, vol. 2012, Article ID 962347, 7 pages, 2012. View at Publisher · View at Google Scholar
  38. L. Mezzasoma, C. Antognelli, and V. N. Talesa, “Atrial natriuretic peptide down-regulates LPS/ATP-mediated IL-1β release by inhibiting NF-kB, NLRP3 inflammasome and caspase-1 activation in THP-1 cells,” Immunologic Research, vol. 64, no. 1, pp. 303–312, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Rudiger, S. Gasser, M. Fischler, T. Hornemann, A. Von Eckardstein, and M. Maggiorini, “Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure,” Critical Care Medicine, vol. 34, no. 8, pp. 2140–2144, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. K. K. Ma, T. Ogawa, and A. J. de Bold, “Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase,” Journal of Molecular and Cellular Cardiology, vol. 36, no. 4, pp. 505–513, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Mezzasoma, L. Cagini, C. Antognelli, F. Puma, E. Pacifico, and V. N. Talesa, “TNF-α regulates natriuretic peptides and aquaporins in human bronchial epithelial cells BEAS-2B,” Mediators of Inflammation, vol. 2013, Article ID 159349, 13 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Testa, M. Yeh, P. Lee et al., “Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension,” Journal of the American College of Cardiology, vol. 28, no. 4, pp. 964–971, 1996. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Omland, A. Aakvaag, V. V. S. Bonarjee et al., “Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide,” Circulation, vol. 93, no. 11, pp. 1963–1969, 1996. View at Publisher · View at Google Scholar · View at Scopus
  44. P. M. Baldini, P. De Vito, A. Martino et al., “Differential sensitivity of human monocytes and macrophages to ANP: a role of intracellular pH on reactive oxygen species production through the phospholipase involvement,” Journal of Leukocyte Biology, vol. 73, no. 4, pp. 502–510, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Morita, N. Ukyo, M. Furuya, T. Uchiyama, and T. Hori, “Atrial natriuretic peptide polarizes human dendritic cells toward a Th2-promoting phenotype through its receptor guanylyl cyclase-coupled receptor A,” The Journal of Immunology, vol. 170, no. 12, pp. 5869–5875, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. M. G. Ghonime, O. R. Shamaa, S. Das et al., “Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling and proteasome function,” Journal of Immunology, vol. 192, no. 8, pp. 3881–3888, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Pan, W. Zhu, J. Ma et al., “Therapeutic effects of continuous infusion of brain natriuretic peptides on postmyocardial infarction ventricular remodelling in rats,” Archives of Cardiovascular Diseases, vol. 104, no. 1, pp. 17–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Suganami, M. Mukoyama, A. Sugawara et al., “Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury,” Journal of the American Society of Nephrology, vol. 12, no. 12, pp. 2652–2663, 2001. View at Google Scholar · View at Scopus
  49. A. J. Ingram, L. James, L. Cai, K. Thai, H. Ly, and J. W. Scholey, “NO inhibits stretch-induced MAPK activity by cytoskeletal disruption,” Journal of Biological Chemistry, vol. 275, no. 51, pp. 40301–40306, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Suhasini, H. Li, S. M. Lohmann, G. R. Boss, and R. B. Pilz, “Cyclic-GMP-dependent protein kinase inhibits the Ras/mitogen-activated protein kinase pathway,” Molecular and Cellular Biology, vol. 18, no. 12, pp. 6983–6994, 1998. View at Publisher · View at Google Scholar · View at Scopus
  51. F. G. Bauernfeind, G. Horvath, A. Stutz et al., “Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression,” The Journal of Immunology, vol. 183, no. 2, pp. 787–791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Zingarelli, M. Sheehan, and H. R. Wong, “Nuclear factor-κB as a therapeutic target in critical care medicine,” Critical Care Medicine, vol. 31, no. 1, pp. S105–S111, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. D. E. Uehling and P. A. Harris, “Recent progress on MAP kinase pathway inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 25, no. 19, pp. 4047–4056, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. A. S. Maisel, “Nesiritide: a new therapy for the treatment of heart failure,” Cardiovascular Toxicology, vol. 3, no. 1, pp. 37–42, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. G. F. Schreiner and A. A. Protter, “B-type natriuretic peptide for the treatment of congestive heart failure,” Current Opinion in Pharmacology, vol. 2, no. 2, pp. 142–147, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Zhao, H. Zhang, Y. Huang et al., “Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-κB activation,” International Immunopharmacology, vol. 17, no. 1, pp. 116–122, 2013. View at Publisher · View at Google Scholar · View at Scopus